Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Regenerx Biopharmaceuticals RGRX

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.


Recent & Breaking News (OTCQB:RGRX)

RegeneRx Announces Participation At The 19th Annual Rodman & Renshaw Global Investment Conference In New York September 10-12, 2017

PR Newswire August 30, 2017

RegeneRx Collaborators Receive Notice of 'Intent to Grant' EU Patent for the Treatment of Peripheral Neuropathy

PR Newswire August 14, 2017

RegeneRx Updates on RGN-259 Phase 3 Dry Eye Trial

PR Newswire July 27, 2017

RegeneRx Collaborators Receive Notice of Allowance of U.S. Patent for the Treatment of Peripheral Neuropathy

PR Newswire June 13, 2017

RegeneRx JV Presents Results of Phase 2b/3 (ARISE-1) Dry Eye Trial at ARVO 2017

PR Newswire May 9, 2017

RegeneRx Releases Annual Letter to Shareholders

PR Newswire March 13, 2017

RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S.

PR Newswire February 27, 2017

RegeneRx Receives Notice of Acceptance for Patent in Australia For Treatment of Neural Injury with Thymosin Beta 4.

PR Newswire January 9, 2017

RegeneRx Receives Notice of Intent to Grant Patent in EU for Treating Neural Injury with Thymosin Beta 4

PR Newswire December 16, 2016

RegeneRx to Present at 9th Annual LD Micro Investor Conference

PR Newswire November 30, 2016

RegeneRx Announces First Patients Enrolled in Phase 3 U.S. Dry Eye Clinical Trial (ARISE-2 Trial) with RGN-259

PR Newswire November 9, 2016

RegeneRx Receives Notice of Allowance for Patent for Tβ4 Eye Drop Formulation

PR Newswire November 2, 2016

RegeneRx Joint Venture Initiates Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome

PR Newswire September 30, 2016

RegeneRx to Present at Rodman & Renshaw 18th Annual Global Investment Conference

PR Newswire August 30, 2016

RegeneRx Receives Notice of Intent to Grant Patent for the Treatment of Patients with Multiple Sclerosis in EU

PR Newswire August 29, 2016

RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter

PR Newswire August 24, 2016

Thymosin Beta 4 Effective in Treatment of Heart Attack Patients

PR Newswire June 14, 2016

RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China

PR Newswire June 1, 2016

RegeneRx Releases Letter to Stockholders

PR Newswire May 17, 2016

Virtus Oil and Gas Announces closing of Producing Wattenberg Minerals and Non-Operated Working Interest in Producing Wells in Western Nebraska

PR Newswire May 17, 2016